Han Lulu, Cai Xiaoning, Zhou Hong
Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Department of Endocrinology, The First Central Hospital of Baoding, Baoding, 071000, China.
Nanomedicine (Lond). 2023 Oct;18(23):1669-1680. doi: 10.2217/nnm-2023-0023. Epub 2023 Nov 1.
Diabetic kidney disease (DKD) is a primary cause for end-stage renal disease, but no specific therapeutic approaches exist. Exosomal miRNAs, a key functional cargo of nanovesicles, play crucial roles in the pathophysiological processes of DKD. Exosomal miRNAs are involved in cell-to-cell transfer of biological information, mediating nephritic inflammation, oxidative stress, apoptosis, autophagy, epithelial-mesenchymal transition and fibrosis. Circulating exosomal miRNAs derived from urine or serum might function as noninvasive prognostic biomarkers for DKD. Exosomal miRNAs from stem cells have been reported to exert beneficial effects on diabetic kidneys, which suggests that these exosomes might function as potential nanotherapy tools for treating DKD. In this review, we have summarized recent studies based on the association between exosomal miRNAs and DKD.
糖尿病肾病(DKD)是终末期肾病的主要病因,但目前尚无特异性治疗方法。外泌体微小RNA(miRNAs)作为纳米囊泡的关键功能性成分,在DKD的病理生理过程中发挥着至关重要的作用。外泌体miRNAs参与生物信息的细胞间传递,介导肾炎性炎症、氧化应激、细胞凋亡、自噬、上皮-间质转化和纤维化。源自尿液或血清的循环外泌体miRNAs可能作为DKD的非侵入性预后生物标志物。据报道,干细胞来源的外泌体miRNAs对糖尿病肾脏具有有益作用,这表明这些外泌体可能作为治疗DKD的潜在纳米治疗工具。在本综述中,我们总结了基于外泌体miRNAs与DKD之间关联的近期研究。